Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression? (Record no. 75746)

MARC details
000 -LEADER
fixed length control field 06049cam a2200397 4500
001 - CONTROL NUMBER
control field NMDX6578
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 120401t2008 xxu||||| |||| 00| 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 02699370
100 ## - MAIN ENTRY--PERSONAL NAME
Personal name Bansi, L.K.
240 ## - UNIFORM TITLE
Uniform title <a href="AIDS">AIDS</a>
245 ## - TITLE STATEMENT
Title Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT)
Date of publication, distribution, etc. 2008
500 ## - GENERAL NOTE
General note NMUH Staff Publications
500 ## - GENERAL NOTE
General note 22
520 ## - SUMMARY, ETC.
Summary, etc. &lt;div style="line-height: 17.999801635742188px;"&gt;&lt;h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"&gt;&lt;span style="font-size: 10pt;"&gt;OBJECTIVE:&lt;/span&gt;&lt;/h4&gt;&lt;p style="margin: 0px 0px 0.5em;"&gt;&lt;span style="font-size: 8pt;"&gt;&lt;span style="font-size: 10pt;"&gt;We investigated whether&amp;nbsp;&lt;span class="highlight"&gt;previous&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;treatment&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;interruptions&lt;/span&gt;&amp;nbsp;are&amp;nbsp;&lt;span class="highlight"&gt;associated&lt;/span&gt;&amp;nbsp;with a raised risk of&amp;nbsp;&lt;span class="highlight"&gt;viral&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;rebound&lt;/span&gt;&amp;nbsp;in individuals who have attained virological suppression.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"&gt;&lt;span style="font-size: 10pt;"&gt;METHODS:&lt;/span&gt;&lt;/h4&gt;&lt;p style="margin: 0px 0px 0.5em;"&gt;&lt;span style="font-size: 10pt;"&gt;All&amp;nbsp;&lt;span class="highlight"&gt;patients&lt;/span&gt;&amp;nbsp;achieving an undetectable&amp;nbsp;&lt;span class="highlight"&gt;viral&lt;/span&gt;&amp;nbsp;load while on&amp;nbsp;&lt;span class="highlight"&gt;therapy&lt;/span&gt;&amp;nbsp;were followed until&amp;nbsp;&lt;span class="highlight"&gt;viral&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;rebound&lt;/span&gt;&amp;nbsp;or the time of the last&amp;nbsp;&lt;span class="highlight"&gt;viral&lt;/span&gt;&amp;nbsp;load. Poisson regression was used to describe the independent impact of&amp;nbsp;&lt;span class="highlight"&gt;treatment&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;interruptions&lt;/span&gt;&amp;nbsp;on&amp;nbsp;&lt;span class="highlight"&gt;rebound&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;rates&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;&lt;h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"&gt;&lt;span style="font-size: 10pt;"&gt;RESULTS:&lt;/span&gt;&lt;/h4&gt;&lt;p style="margin: 0px 0px 0.5em;"&gt;&lt;span style="font-size: 10pt;"&gt;A total of 12,977&amp;nbsp;&lt;span class="highlight"&gt;patients&lt;/span&gt;&amp;nbsp;from the United Kingdom Collaborative HIV Cohort (UK CHIC) Study achieved a&amp;nbsp;&lt;span class="highlight"&gt;viral&lt;/span&gt;&amp;nbsp;load of less than 50 copies/ml. These&amp;nbsp;&lt;span class="highlight"&gt;patients&lt;/span&gt;&amp;nbsp;contributed a total of 37,314 person-years of follow-up. The overall&amp;nbsp;&lt;span class="highlight"&gt;rebound&lt;/span&gt;&amp;nbsp;rate was 8.07 (7.78, 8.36) per 100 person-years. In adjusted analyses,&amp;nbsp;&lt;span class="highlight"&gt;rates&lt;/span&gt;&amp;nbsp;of&amp;nbsp;&lt;span class="highlight"&gt;viral&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;rebound&lt;/span&gt;&amp;nbsp;were up to 64%&amp;nbsp;&lt;span class="highlight"&gt;higher&lt;/span&gt;&amp;nbsp;(rate ratio 1.64; 1.43, 1.88) in those who had previously interrupted&amp;nbsp;&lt;span class="highlight"&gt;therapy&lt;/span&gt;&amp;nbsp;compared with those who had not.&amp;nbsp;&lt;span class="highlight"&gt;Patients&lt;/span&gt;&amp;nbsp;who had interrupted at detectable&amp;nbsp;&lt;span class="highlight"&gt;viral&lt;/span&gt;&amp;nbsp;loads had up to a 74% (1.74; 1.42, 2.14)&amp;nbsp;&lt;span class="highlight"&gt;higher&lt;/span&gt;&amp;nbsp;chance of rebounding compared with those who had not interrupted with a detectable&amp;nbsp;&lt;span class="highlight"&gt;viral&lt;/span&gt;&amp;nbsp;load. We found no evidence to suggest interrupting&amp;nbsp;&lt;span class="highlight"&gt;treatment&lt;/span&gt;&amp;nbsp;at an undetectable&amp;nbsp;&lt;span class="highlight"&gt;viral&lt;/span&gt;&amp;nbsp;load was&amp;nbsp;&lt;span class="highlight"&gt;associated&lt;/span&gt;&amp;nbsp;with&amp;nbsp;&lt;span class="highlight"&gt;viral&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;rebound&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;&lt;h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"&gt;&lt;span style="font-size: 10pt;"&gt;CONCLUSION:&lt;/span&gt;&lt;/h4&gt;&lt;p style="margin: 0px 0px 0.5em;"&gt;&lt;span style="font-size: 8pt;"&gt;&lt;span style="font-size: 10pt;"&gt;Among&amp;nbsp;&lt;span class="highlight"&gt;patients&lt;/span&gt;&amp;nbsp;with an undetectable&amp;nbsp;&lt;span class="highlight"&gt;viral&lt;/span&gt;&amp;nbsp;load, having previously interrupted&amp;nbsp;&lt;span class="highlight"&gt;therapy&lt;/span&gt;&amp;nbsp;while the&amp;nbsp;&lt;span class="highlight"&gt;viral&lt;/span&gt;&amp;nbsp;load was detectable is&amp;nbsp;&lt;span class="highlight"&gt;associated&lt;/span&gt;&amp;nbsp;with a raised risk of&amp;nbsp;&lt;span class="highlight"&gt;rebound&lt;/span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Benzie, A.A.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Phillips, A.N.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Portsmouth, S.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Hill, T.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Leen, C.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Schwenk, A.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Johnson, M.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Anderson, J.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Gilson, R.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Easterbrook, P.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Gazzard, B.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Fisher, M.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Orkin, C.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Porter, K.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Pillay, D.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Taylor, G.P.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Walsh, J.C.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Sabin, C.A.
710 ## - ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element UK Collaborative HIV Cohort (UK CHIC) Study.
856 ## - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Are+previous+treatment+interruptions+associated+with+higher+viral+rebound+rates+in+patients+with+viral+suppression%3F">http://www.ncbi.nlm.nih.gov/pubmed/?term=Are+previous+treatment+interruptions+associated+with+higher+viral+rebound+rates+in+patients+with+viral+suppression%3F</a>
Holdings
Withdrawn status Lost status Damaged status Not for loan Collection code Home library Current library Shelving location Date acquired Total Checkouts Date last seen Price effective from Koha item type
        Staff publications for NMDX Ferriman information and Library Service (North Middlesex) Ferriman information and Library Service (North Middlesex) Shelves 07/06/2022   07/06/2022 07/06/2022 Book
London Health Libraries Koha Consortium privacy notice